Please provide your email address to receive an email when new articles are posted on . The FDA did not approve the supplemental biologics license application for Eylea HD. The application would have ...
88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 weeks, in this extension study of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback